PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been given an average rating of “Moderate Buy” by the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $12.25.

A number of analysts have commented on PYPD shares. Wall Street Zen upgraded PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings downgraded PolyPid from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Wednesday, February 11th.

Institutional Trading of PolyPid

A number of hedge funds have recently modified their holdings of the company. AIGH Capital Management LLC lifted its position in shares of PolyPid by 18.7% in the 1st quarter. AIGH Capital Management LLC now owns 1,593,587 shares of the company’s stock worth $6,980,000 after acquiring an additional 250,615 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid in the 4th quarter worth approximately $451,000. XTX Topco Ltd raised its holdings in shares of PolyPid by 50.0% in the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock worth $142,000 after buying an additional 10,888 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of PolyPid in the 1st quarter worth approximately $81,000. Finally, Jane Street Group LLC acquired a new position in shares of PolyPid in the 4th quarter worth approximately $66,000. Institutional investors own 26.47% of the company’s stock.

PolyPid Stock Up 3.8%

Shares of NASDAQ:PYPD opened at $4.38 on Friday. The business has a 50 day moving average price of $4.39 and a 200 day moving average price of $4.24. PolyPid has a twelve month low of $2.44 and a twelve month high of $5.12. The company has a market cap of $83.57 million, a price-to-earnings ratio of -2.29 and a beta of 1.41.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. Analysts anticipate that PolyPid will post -1.5 EPS for the current year.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.